Gyroscope Therapeutics
Chloe Parsons is an experienced professional in clinical trials management, currently serving as a Global Trial Manager at Novartis from January 2022 to April 2024. Prior experience includes roles as a Clinical Trials Associate at Gyroscope Therapeutics from September 2020 to December 2022 and at Biogen from June 2019 to July 2020. Chloe began their career as a Clinical Trial Coordinator at Nightstar Therapeutics from March 2016 until the company's acquisition by Biogen in June 2019. Additional experience includes positions as a Community Fundraiser & Administrator at Ellen MacArthur Cancer Trust and as a Pupil Specific Teaching Assistant at Alexandra Infant School. Chloe holds a Bachelor’s Degree in Social Psychology and Sociology from the University of Essex, obtained in 2014.
Gyroscope Therapeutics
Gyroscope Therapeutics is a clinical-stage retinal gene therapy company developing gene therapy beyond rare diseases to treat a leading cause of blindness, dry age-related macular degeneration (AMD).